TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33136471
Drug: Irinotecan (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan (60 mg/m2, days 1, 8, 15) plus cisplatin (60 mg/m2, day 1)
Study: 33136471
Drug: Etoposide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoposide (100 mg/m2, days 1‐3) plus cisplatin (80 mg/m2, day 1)
Study: 35368946
Drug: Basic chemotherapy
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic chemotherapy combined with docetaxel
Study: 34791970
Drug: NZBC extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: NZBC extract (210 mg of anthocyanins) for 7 days
Study: 34791970
Drug: NZBC extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: NZBC extract (210 mg of anthocyanins) for 14 days
Study: 34791970
Drug: NZBC extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: NZBC extract (210 mg of anthocyanins) for 7 days during walking
Study: 34791970
Drug: NZBC extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: NZBC extract (210 mg of anthocyanins) for 14 days during walking
Study: 32112999
Drug: Topical lidocaine-prilocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lidocaine-prilocaine cream
Study: 32112999
Drug: Rectal meloxicam
Normalized name: meloxicam Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal meloxicam suppository 15 mg
Study: 35455529
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy via telerehabilitation (5 sessions per week, 1 hour each for 3 weeks)
Study: 34872405
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (n=21)
Study: 32598752
Drug: rabeprazole 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: rabeprazole 40 mg
Study: 32598752
Drug: standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard dose rabeprazole
Study: 32598752
Drug: IL‐1β CC
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL‐1β CC genotype
Study: 33980690
Drug: Target LDL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target LDL cholesterol of <70 mg/dL
Study: 34963300
Drug: Target LDL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target LDL cholesterol of 100±10 mg/dL
Study: 34623761
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of perioperative antibiotics (piperacillin + tazobactam - 4.5 g intravenous at fixed 8 hourly intervals)
Study: 34623761
Drug: Nine doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nine doses of perioperative antibiotics (piperacillin + tazobactam - 4.5 g intravenous at fixed 8 hourly intervals)
Study: 34623761
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of perioperative antibiotics
Study: 34623761
Drug: Nine doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nine doses of perioperative antibiotics
Study: 35577410
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) for 4 months
Study: 32870340
Drug: Vaginal hysterectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal hysterectomy with uterosacral ligament suspension
Study: 32740291
Drug: 6.4% maltodextrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.4% maltodextrin (CHO) solution
Study: 32740291
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (WAT, PLA, CHO)
Study: 35748295
Drug: Corrected insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corrected insulin response (CIR)
Study: 33141785
Drug: Dance/Movement Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dance/Movement Therapy (DMT)
Study: 33141785
Drug: Verbal Treatment
Normalized name: HERBAL MISCELLANEOUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verbal Treatment as Usual (TAU)
Study: 35593501
Drug: Isoflavone supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavone supplementation (single oral tablet of soy extract for 30 days)
Study: 35593501
Drug: Estradiol treatment
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol treatment (0.5 μg subcutaneous injection in sesame oil for 30 days)
Study: 35593501
Drug: Control (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (subcutaneous injections of vehicle and oral placebo for 30 days)
Study: 34418400
Drug: Tolebrutinib 5
Normalized name: Tolebrutinib
DrugBank: Tolebrutinib (DB18715)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolebrutinib 5 mg
Study: 34418400
Drug: Tolebrutinib 15
Normalized name: Tolebrutinib
DrugBank: Tolebrutinib (DB18715)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolebrutinib 15 mg
Study: 34418400
Drug: Tolebrutinib 30
Normalized name: Tolebrutinib
DrugBank: Tolebrutinib (DB18715)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolebrutinib 30 mg
Study: 34418400
Drug: Tolebrutinib 60
Normalized name: Tolebrutinib
DrugBank: Tolebrutinib (DB18715)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolebrutinib 60 mg
Study: 34724345
Drug: Tolebrutinib 120
Normalized name: Tolebrutinib
DrugBank: Tolebrutinib (DB18715)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolebrutinib 120 mg
Study: 34724345
Drug: Tolebrutinib 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolebrutinib 7.5 mg (multiple ascending dose)
Study: 34724345
Drug: Tolebrutinib 15
Normalized name: Tolebrutinib
DrugBank: Tolebrutinib (DB18715)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolebrutinib 15 mg (multiple ascending dose)
Study: 34724345
Drug: Tolebrutinib 30
Normalized name: Tolebrutinib
DrugBank: Tolebrutinib (DB18715)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolebrutinib 30 mg (multiple ascending dose)
Study: 34724345
Drug: Tolebrutinib 60
Normalized name: Tolebrutinib
DrugBank: Tolebrutinib (DB18715)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolebrutinib 60 mg (multiple ascending dose)
Study: 34724345
Drug: Tolebrutinib 90
Normalized name: Tolebrutinib
DrugBank: Tolebrutinib (DB18715)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolebrutinib 90 mg (multiple ascending dose)
Study: 33475318
Drug: Nomogram based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nomogram based on combination model
Study: 32919897
Drug: Ultrasound-guided dextrose
Normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided dextrose prolotherapy (2 cc dextrose 20% injection, 2 sessions)
Study: 32919897
Drug: Radial extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial extracorporeal shock wave therapy (ESWT, 3 sessions)
Study: 35681620
Drug: Everolimus (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (10 mg QD)
Study: 35681620
Drug: Pasireotide-LAR (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide-LAR (60 mg Q4 weeks)
Study: 35681620
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Everolimus and Pasireotide-LAR
Study: 33428870
Drug: 2 +
Normalized name: dHER2 + AS15 ASCI
DrugBank: SB719125 (DB16753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 + 1 schedule of the 13-valent pneumococcal conjugate vaccine (PCV13) with 4CMenB at 2, 4, and 12 months of age.
Study: 33428870
Drug: 1 +
Normalized name: Prenatal Vitamins Oral Tablet [PRENAZYME 1 + 1]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 + 1 schedule of the 13-valent pneumococcal conjugate vaccine (PCV13) with 4CMenB at 3 and 12 months of age.
Study: 34135111
Drug: Daily energy
Normalized name: CVS Daily Energy Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily energy restriction (75:75)
Study: 35792962
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g amoxicillin administered 1 hour before surgery, followed by 1.5 g each for the first 3 postoperative days
Study: 33534047
Drug: Methylprednisolone (MP)
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone (MP) 40 mg bid for 3 days followed by 20 mg bid for 3 days
Study: 32155883
Drug: DHA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA supplementation (1250 mg daily for 12 weeks)
Study: 32394655
Drug: Omeprazole enteric
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole enteric capsules (OME), 20 mg twice a day for 8 weeks
Study: 33062629
Drug: Both formulations
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both formulations (test and reference)
Study: 33561214
Drug: SQ-LNS (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQ-LNS (800 μg RE/20g) during pregnancy and the first 6 mo postpartum; children received SQ-LNS (400 μg RE/20 g) from 6 to 18 mo of age.
Study: 33561214
Drug: Multiple micronutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple micronutrients (MMN; 800 μg retinol equivalent (RE)/capsule) during pregnancy only.
Study: 33561214
Drug: SQ-LNS (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQ-LNS (400 μg RE/20 g) for children from 6 to 18 mo of age.
Study: 33561214
Drug: Multiple micronutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple micronutrients (MMN) and Iron and folic acid (IFA) for children (no supplement).
Study: 32613240
Drug: Physiologic E2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiologic E2 (∼180 pg/ml) with P4 10 mg/day
Study: 32613240
Drug: Moderately supraphysiologic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderately supraphysiologic E2 (600-800 pg/ml) with P4 10 mg/day
Study: 32613240
Drug: Supraphysiologic E2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supraphysiologic E2 (2000 pg/ml) with P4 10 mg/day
Study: 33766497
Drug: BH4 treatment
Normalized name: 6R-BH4
DrugBank: Sapropterin (DB00360)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BH4 treatment
Study: 34708917
Drug: Pentazocine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentazocine (0.5 mg/kg)
Study: 34214362
Drug: Centella asiatica
Normalized name: Centella asiatica
DrugBank: Centella asiatica (DB14256)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Centella asiatica cream applied twice a day
Study: 34214362
Drug: Ceramide cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceramide cream applied twice a day
Study: 33081849
Drug: Hydroxychloroquine 400
Normalized name: hydroxychloroquine 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine 400 mg twice on first day followed by 400 mg daily for 10 days + Ribavirin (1.2 g loading dose followed by 600 mg every 12 hours for 10 days) + Standard Treatment (STNS)
Study: 33081849
Drug: Standard Treatment
Normalized name: Azo-Standard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard Treatment (STNS)
Study: 33081849
Drug: Lopinavir (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir (200 mg) + Ritonavir (50 mg) two tablets twice daily + Ribavirin (1.2 g loading dose followed by 600 mg every 12 hours for 10 days) + Standard Treatment (STs)
Study: 33081849
Drug: Hydroxychloroquine 400
Normalized name: hydroxychloroquine 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine 400 mg twice on first day followed by 400 mg daily for 10 days + Ribavirin (1.2 g loading dose followed by 600 mg every 12 hours for 10 days) + Standard Treatment (STs)
Study: 33081849
Drug: Standard Treatment
Normalized name: Azo-Standard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard Treatment (STs)
Study: 32450838
Drug: Regular treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular treatment interval cohort (3 initial monthly IVT-AFL injections followed by regular injections every 2 months)
Study: 32450838
Drug: Irregular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irregular treatment interval cohort with initial doses (3 initial monthly IVT-AFL injections)
Study: 32450838
Drug: Irregular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irregular treatment interval cohort without initial doses
Study: 33104981
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate nasal spray 55 μg
Study: 33104981
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group without intranasal steroid
Study: 33171964
Drug: Aspartame (0.425
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspartame (0.425 g, 14% of ADI)
Study: 33171964
Drug: Sucralose (0.136
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralose (0.136 g, 20% of ADI)
Study: 33835666
Drug: Immuno-oncology (IO)
Normalized name: Io-Shield
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immuno-oncology (IO) based systemic treatment
Study: 32098739
Drug: Individually-tailored educational
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individually-tailored educational videos about maternal and infant vaccines and the cocooning strategy
Study: 32098739
Drug: Intention to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intention to receive maternal influenza vaccine, perceived safety of maternal Tdap vaccine, perceived efficacy of maternal influenza vaccine, perceived susceptibility to and severity of influenza during pregnancy, trust in vaccine information from CDC and academic institutions
Study: 32098739
Drug: Uncertainty about
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uncertainty about infant vaccine intentions
Study: 33650471
Drug: Antibiotics prescribed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics prescribed (154 patients, 38.1%)
Study: 33650471
Drug: No antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotics prescribed (250 patients, 61.9%)
Study: 35830133
Drug: Nano-suspension of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nano-suspension of Talaromyces flavus at concentrations of 1, 4, and 5 per thousand (soil addition method)
Study: 35830133
Drug: Registered formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Registered formulation of Talaromin (seed impregnation and soil addition methods)
Study: 33082342
Drug: Hydroxychloroquine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine therapy (400 mg twice daily for seven days)
Study: 35662514
Drug: Neostigmine (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine (0.05 mg/kg) + Atropine (0.02 mg/kg)
Study: 35153119
Drug: Sugammadex (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex (1 mg/kg) after Neostigmine
Study: 34600264
Drug: ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron 4 mg twice daily
Study: 33685776
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) antimicrobials
Study: 33685776
Drug: Oral (PO)
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral (PO) antimicrobials
Study: 32645765
Drug: Nitric oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitric oxide administration
Study: 35834633
Drug: BSRGE extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: BSRGE extract (30 mg of GABA per day)
Study: 35961842
Drug: Reflexology treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reflexology treatment along with usual medical care
Study: 32499757
Drug: Anastrozole (AI)
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anastrozole (AI) plus weight loss (WL) at 1 mg daily for 6 months
Study: 35151367
Drug: Active hexose
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active hexose correlated compound (AHCC)
Study: 34875139
Drug: QR678 Neo®
Approvals — FDA: no, EMA: no, PMDA: no
Description: QR678 Neo® hair growth factor formulation
Study: 32677375
Drug: Peramivir 600
Normalized name: peramivir 600 mg in 60 mL INTRAVENOUS SOLUTION [Rapivab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peramivir 600 mg on two consecutive days (peramivir-repeat)
Study: 32677375
Drug: Peramivir 300
Normalized name: Peramivir
DrugBank: Peramivir (DB06614)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Peramivir 300 mg single dose (peramivir-single)
Study: 34857578
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy plus axillary treatment (ANC or axillary RT)
Study: 34857578
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy (standard care)
Study: 32510754
Drug: N. sativa
Approvals — FDA: no, EMA: no, PMDA: no
Description: N. sativa oil (1,000 mg daily for 8 weeks)
Study: 34928294
Drug: Daily low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily low-dose prednisolone (15 mg/m2 daily for 6 days)
Study: 34928294
Drug: Daily low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily low-dose prednisolone
Study: 33927582
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil tablets (250 mg) - various brands
Study: 32197931
Drug: Low-dose thoracic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose thoracic CT scan
Study: 32197931
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of smoking cessation and lung cancer screening
Study: 36065795
Drug: Spironolactone (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (up to 50 mg/day)
Study: 36209245
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (5 mg in 100 ml isotonic saline)
Study: 36209245
Drug: Placebo (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (100 ml isotonic saline only)
Study: 35436810
Drug: Subanesthetic dose
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subanesthetic dose of esketamine 0.125 mg·kg‐1·h‐1 (group ES1)
Study: 35436810
Drug: Subanesthetic dose
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subanesthetic dose of esketamine 0.250 mg·kg‐1·h‐1 (group ES2)
Study: 34262052
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) route
Study: 35709811
Drug: Hepatitis A
Normalized name: HEPATITIS A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis A virus vaccine (control)
Study: 35016205
Drug: DAV132 (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAV132 (7.5 g, 3 times a day, orally)
Study: 33794784
Drug: VSL#3® probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: VSL#3® probiotic supplementation (2 sachets twice daily for 10 weeks)
Study: 32989783
Drug: Hair Follicle
Normalized name: BIOTIN 2 g in 30 mL TOPICAL OIL [Reactivate Hair Follicles]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hair Follicle Cell Suspension (HFCS)
Study: 32989783
Drug: Epidermal Cell
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidermal Cell Suspension (ECS)
Study: 32391548
Drug: CEMA cutpoint
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEMA cutpoint of 27 pmol/mL urine
Study: 32391548
Drug: Different cotinine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different cotinine cutpoints (10-30 ng/mL)
Study: 33770484
Drug: Dexamethasone plus
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone plus oseltamivir (40 mg/day for 4 days + 75 mg twice a day for 10 days)
Study: 32657903
Drug: Massage application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage application with ultrasound gel (placebo, n = 15)
Study: 32390705
Drug: 1 L-PEG
Normalized name: Peg/L-asparaginase
DrugBank: Pegaspargase (DB00059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 L-PEG preparation (Plenvu®)
Study: 32390705
Drug: 2 L-PEG
Normalized name: Peg/L-asparaginase
DrugBank: Pegaspargase (DB00059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 L-PEG preparation (Moviprep® or Clensia®)
Study: 32390705
Drug: 4 L-PEG
Normalized name: Peg/L-asparaginase
DrugBank: Pegaspargase (DB00059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 L-PEG preparation (Selgesse®)
Study: 39710693
Drug: High-dose dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dexamethasone
Study: 32015090
Drug: Intravenous rt-PA
Normalized name: rt-PA
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous rt-PA
Study: 34313917
Drug: Diphenhydramine 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine 0.4 mg/kg, acetaminophen 1g, ondansetron 4 mg
Study: 32661108
Drug: Afrezza high
Normalized name: Afrezza
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Afrezza high dose (AH)
Study: 32661108
Drug: Afrezza low
Normalized name: Afrezza
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Afrezza low dose (AL)
Study: 32661108
Drug: Standard SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard SC rapid-acting insulin (aspart)
Study: 35718438
Drug: Zygomatic implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zygomatic implants
Study: 616084148
Drug: Half-dose verteporfin
Normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Half-dose verteporfin photodynamic therapy (hd-PDT)
Study: 616084148
Drug: 689 nm
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 689 nm laser treatment
Study: 32653031
Drug: Monthly administration
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly administration of solid forms (tablets, capsules)
Study: 32653031
Drug: Weekly administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly administration of solid forms (tablets, capsules)
Study: 33040561
Drug: Remifentanil 1
Normalized name: remifentanil 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 1 μg/kg (Rem group, n=51)
Study: 33040561
Drug: Propofol 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 1.0 mg/kg (Pro group, n=48)